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only 50% of the average salary the costs outweigh the beneﬁt.
CONCLUSIONS: The beneﬁt to an employer depends on the
organization of the company and the value of reducing illness
related work absence. These results indicate that providing
inﬂuenza treatment may be a cost-saving intervention for
employers. In addition, employees will beneﬁt from improved
quality of life.
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OBJECTIVES: In immunocompromised patients, presumed 
systemic fungal infections (SFI) are treated empirically with an
intravenous (IV) antifungal to reduce the occurrence of docu-
mented infections and associated mortality. Amphotericin B (AB)
remains the treatment of choice. The toxicity of conventional AB
(CAB) often results in discontinuation or suboptimal dosing.
Liposomal or lipid formulations of AB (LAB), with improved
toxicity proﬁle, are extremely expensive. The objective was to
compare the cost-effectiveness of intravenous itraconazole
(IVitra) with CAB and LAB as empirical treatment of presumed
SFI in neutropenic cancer and bone marrow transplant (BMT)
patients. METHODS: A medical decision tree was developed,
including probabilities of toxicity, response, pathogen documen-
tation and 2nd line treatments. Clinical data were obtained from
randomized trials comparing IVitra with CAB (n = 392) and CAB
with LAB (n = 687). Resource use was obtained via modiﬁed
Delphi consensus panel, unit costs from ofﬁcial sources (public
payer perspective). Cost-effectiveness was expressed as cost 
per additional “responder” (deﬁned as patient without fever or
major toxicity). RESULTS: The total cost per neutropenic cancer
patient was lowest for IVitra (7486€), followed by CAB (9721€)
and LAB (11,956€). The same cost ranking was obtained in BMT
patients, however with higher hospitalization costs. The vari-
ables accounting for cost differences between strategies were 1st
and 2nd line antifungal drug costs. In cost-effectiveness analysis,
IVitra was dominant over CAB combining greater “effective-
ness” (because of less toxicity) and lower costs. The incremen-
tal cost-effectiveness ratios for LAB over IVitra in neutropenic
cancer and BMT patients were 188,638€/“responder” and
206,865€/“responder” respectively. CONCLUSIONS: IVitra
was shown to be a cost-effective empirical treatment for pre-
sumed SFI in neutropenic cancer and BMT patients and to be
cost saving compared to both CAB and LAB. These conclusions
are similar to those for UK, Germany, Italy and Sweden, in which
the same analysis was performed earlier.
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OBJECTIVES: Most decision-analyses for chronic hepatitis C
(CHC) treatment ignore co-morbid illness associated with CHC,
leading to overly optimistic results. Therefore, we sought: 1) to
predict population-based clinical and economic burden of CHC
and associated diseases for the next 20 years in Germany, and
2) to examine the potential impact of different antiviral treat-
ment (AVT) policies. METHODS: The German Hepatitis C
Model (GEHMO), a validated and published CHC Markov
model, was linked to German CHC prevalence and incidence
data to project the morbidity, mortality and costs for all treat-
able patients with known CHC and elevated transaminases in
Germany. The model considered HCV genotype and CHC-asso-
ciated diseases (e.g., HIV co-infection, hemophilia, extra-hepatic
manifestations) and evaluated the following policies: 1) no AVT,
2) interferon monotherapy, and 3) interferon plus ribavirin, and
(4) pegylated interferon plus ribavirin. For each policy, the model
calculated the incidence of clinical complications, CHC-related
deaths, population life years (LY), quality-adjusted life years
(QALY), costs, and incremental cost-effectiveness ratios (ICER).
We used treatment efﬁcacy data from meta-analyses of random-
ized clinical trials and literature-based epidemiologic data on co-
morbidities. We adopted a societal perspective with a 3% annual
discount rate. RESULTS: In the absence of AVT during the next
20 years, HCV would cause more than 16,000 CHC-related
deaths and 29,000 cases of liver cirrhosis leading to 1200 liver
transplantations. Peginterferon plus ribavirin would prevent
about half of these complications and would add about 53,000
LY (or 49,000 QALYs) at a total cost of 1.3€ billion (undis-
counted values). In the discounted lifetime analysis, peginter-
feron plus ribavirin was the most effective strategy with an ICER
of 23,000€/QALY compared with interferon monotherapy (next
non-dominated strategy). CONCLUSIONS: Incorporating co-
morbid illnesses associated with CHC increased the ICER 
of peginterferon plus ribavirin, but treatment remained cost-
effective and would halve the burden of disease.
METHODS & CONCEPTS I
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OBJECTIVE: To evaluate three measures of compliance by
applying established methodologies for each to one population.
METHODS: Prescription claims data for 1164 patients receiv-
ing a chronic lipid-lowering medication (a combination product
versus a statin) in 2002–2003 were obtained; MPRs, PDCs, and
ELPTs were calculated. Because each method has different inclu-
sion criteria, the measures were analyzed for three different
subsets of the overall population. A second set of analyses was
conducted on a fourth subset of patients (those included in all
three of the other analyses) to evaluate the impact of inclusion
criteria on the endpoints. Logistic regression analyses were con-
ducted for each measure to determine the probability of being
categorized as “compliant” by established deﬁnitions. RESULTS:
The results differed depending on the methodology used, sug-
gesting each measure evaluates a different aspect of overall com-
pliance. MPR analysis demonstrated higher overall compliance
rates with the combination product versus statins (p = 0.001).
PDC analysis demonstrated lower compliance rates with the
combination product versus statins (2nd quarter p = 0.003, 4th
quarter p = 0.011). ELPT analysis also demonstrated lower com-
pliance rates for the combination product versus statins (6th
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month p = 0.022, 9th month p = 0.008). CONCLUSIONS: Each
measure evaluates a different aspect of overall compliance. MPR
methodology, which measures the degree of prescription-ﬁlling
during treatment and does not factor in duration of treatment,
may be considered a surrogate measure for adherence. ELPTs 
are a pure measure of persistence, useful even in sub-optimally
adherent patients. PDCs are a composite measure of adherence
and persistence where the degree of prescription-ﬁlling is
reported quarterly in an attempt to describe patient behavior 
longitudinally.
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OBJECTIVES: In economic evaluation of health care pro-
grammes, productivity costs are often overestimated, because
compensation of lost work is neglected. This study tested the
conclusions of a small previous study (Severens et al. 1998)
which indicated that short-term work absence often is compen-
sated for during normal work hours, thereby leading to limited
productivity costs. METHODS: We studied work absence and
compensation of lost work in ﬁve different patient populations
(psoriasis, low back pain, chronic fatigue syndrome, rheumatoid
arthritis and persistent dyspepsia) and one employee population
(workers of a pharmaceutical company). RESULTS: this study
showed that only About 70–75% of lost work hours were com-
pensated by the absentee or colleagues during normal working
hours. Between 25–30% of the productivity costs as calculated
by the classical method remained, if productivity costs were only
calculated when extra efforts were needed. For 1 day absence
only in 17–19% of the cases work absence resulted in produc-
tivity costs were relevant, while this was 35%–39% for absence
of two weeks or longer. Measurement of the compensating mech-
anisms seemed to be valid, because of the large since the agree-
ment between the opinion of supervisors and their employees
whether compensation takes productivity costs. The measure-
ment of compensating mechanisms, seemed to be valid. Also, for
different occupations different compensating mechanisms were
reported in the expected direction. In our study populations,
Compensating mechanisms differed with occupational charac-
teristics, like part-time work, managerial work and shift work.
For example, higher educated workers more often compensate
for lost work themselves. CONCLUSIONS: Including compen-
sation reduces productivity costs due to absence from work to a
considerable extent. Nevertheless, we advise researchers to take
a broad range for correction, because for some compensation
mechanisms the consequences for productivity costs may vary
between settings.
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OBJECTIVES: To critically appraise published cost-utility analy-
ses of interventions in child and adolescent health care in terms
of the methods used to estimate quality-adjusted life years
(QALYs). METHODS: A comprehensive search of computerised
databases (e.g. Medline, Embase) was undertaken to identify
cost-utility studies published prior to April 2004. Studies were
categorised according to the methods used to describe health
status, the valuation technique and source of preferences. The
methods were compared with the guidelines of the U.S. Panel on
Cost-effectiveness in Health and Medicine and the National
Institute for Clinical Excellence (NICE) in England and Wales
which recommend the use of a generic health status classiﬁca-
tion system (e.g. HUI, EQ-5D), a choice-based valuation method
(e.g. SG or TTO), and preferences of the general population.
RESULTS: Fifty-four studies were reviewed, of which 34 (63%)
were published in the latter 5 years. A generic health status 
classiﬁcation instrument was used in 22 (35%) cases; the remain-
der developed study speciﬁc health state descriptions or elicited
preferences directly from patients or proxies. In 7 cases (11%),
sources were unclear. Utility values were elicited by using choice-
based techniques in 28 cases (42%), either as tariffs for health
status classiﬁcation instruments (17 cases) or by directly valuing
health state descriptions or patient health (11 cases). Commu-
nity preferences were only used in 23 cases (37%). Four studies
aggregated QALYs for mother/child or family/child pairs without
giving any theoretical justiﬁcation. CONCLUSIONS: Although
the number of cost utility studies is increasing exponentially, 
the majority of studies did not adhere to standard recommen-
dations with little improvement over time. Further research is
warranted to develop appropriate methods to measure and value
child health beneﬁts within the QALY framework. In the interim,
an expert panel is needed to provide guidance for cost-utility
analysis of paediatric interventions to make studies more 
consistent.
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OBJECTIVE: Drug-eluting stents (DES) elute drugs that prevent
coronary restenosis after a percutaneous revascularization. The
cost of DES is quite high therefore imposing a relevant burden
to hospital and NHS budgets. Patients selection and reimburse-
ment policies need to be settled according to a large amount of
clinical (number and anatomy of revascularized vessels, diabetes,
unstable angina), economic (local cost of devices and procedures)
and organizational variables (adoption rate of different types of
DES and BMS, number of stent/procedure, shift from surgical to
DES revascularization). The resulting decision models are usually
blamed for high complexity but poor completeness and low
transparency. METHODS: Bayesian networks (BN) are close
acyclic graphs displaying value nodes, probability nodes and,
possibly, decision nodes (inﬂuence diagrams). We explored the
application of BN to policy selection for DES use, in both the
NHS and the hospital perspective. Three commercial softwares
were compared: Netica, TreeAgePro, HuginLite. Beta and
gamma distributions were used to represent the probability of
conditions/events and unit costs, respectively. Log-normal distri-
butions were used to model relative risks. RESULTS: BN mod-
eling of the DES problem was feasible with the three softwares
and required 35–40 nodes. We tested ﬁve types of restriction
policies to DES use, anchored to: 1) the presence of diabetes; 2)
the number of vessels to be revascularized; 3) the overall risk of
restenosis; 4) a cutoff adoption rate of DES; and 5) a cutoff
budget. We could verify that ﬂexibility, directness and trans-
parency varied among the softwares. Also software modalities to
manage uncertainty and to report the results had different
appeal. CONCLUSIONS: BN allows rapid and transparent esti-
mations of the local/speciﬁc economic impact of several differ-
